Skip Navigation
Search Menu
Find an Expert

 


Christopher Jordan Gamper, M.D., Ph.D.

Photo of Dr. Christopher Jordan Gamper, M.D., Ph.D.

Assistant Professor of Oncology

Male

Expertise: Bone Marrow Transplant, Medical Oncology, Pediatric Oncology, Pediatrics

Research Interests: Regulation of T cell effector function in the setting of cancer immunotherapy and graft versus host disease ...read more

Request an Appointment

I live in Maryland

410-955-8751
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

The Johns Hopkins Hospital (Main Entrance)
Appointment Phone: 410-955-8751

1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287 map
Phone: 410-955-8751
Fax: 410-955-1002

Background

When it comes to discussing the realities of current cancer therapies, Christopher Gamper, M.D., PhD., doesn't mince words. "Conventional therapy knocks down the immune response. In a way, what we do to treat patients directly subverts what we're trying to accomplish," he says matter-of-factly, referring to the immune-suppressing effects of chemotherapy and radiation.

It's a grim reality that Dr. Gamper refuses to accept lightly. In fact, he's chosen to dedicate his research in pediatric oncology to finding alternate, less toxic methods of treating cancer. Subsequently, he's honing in on immunotherapy—a method of treatment that focuses on triggering the body's immune system to recognize and respond to cancerous cells.

Though it sounds like a fairly straightforward concept, Dr. Gamper cautions that immunology, as well as patients' response to it, is an extremely complex matter. "We take the immune system for granted, but the actual sophistication behind this seemingly mundane thing is incredibly complicated," Dr. Gamper says.

Applying immunology to patients with cancer is particularly daunting, Dr. Gamper explains, because their systems are already immune-suppressed. "The trick," he says, "is how to uncover chinks in the armor, so to speak, so we can turn off the defense mechanism of tumors."

While researching new ways to treat cancer, Dr. Gamper also focuses on improving how existing therapies are administered. "We want to do what we can to spare toxicity [inherent in chemotherapy treatment]—not just to have patients survive cancer," he says.

This pursuit involves analyzing genetic differences that may explain why not all patients respond similarly to chemotherapy. "Some patients exhibit an excellent response rate to treatment. Others may have a genetic factor that predisposes them to a high rate of relapse. We're looking at changes in therapy based on these differences," Dr. Gamper says.

As he soldiers on to find treatments that are less toxic and ultimately more effective for children with cancer, Dr. Gamper is buoyed by the strength of the families he encounters. "They say to us, 'I want to help other people in the world learn more.'" He believes that it's this spirit of generosity, whereby parents enroll their children in clinical trials knowing they personally may not reap the benefits, that has hastened the progress of pediatric oncology.

"Scientific progress has exploded: our understanding of genetic underpinnings, the potential for treatments to turn off genetic switches. We're just beginning to incorporate these new strategies that hold out the most hope," Dr. Gamper says.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

Education

Degrees

  • MD PhD, Columbia University College of Physicians and Surg (2001)

Residencies

  • Johns Hopkins University School of Medicine / Pediatrics (2004)

Fellowships

  • Johns Hopkins University School of Medicine / Pediatric Oncology (2008)

Board Certifications

  • American Board of Pediatrics / Pediatric Hematology-Oncology (2009)
  • American Board of Pediatrics / Pediatrics (2004, 2016)

Research & Publications

Clinical Trials

Hematopoietic stem cell transplant and cancer immunotherapy.

Selected Publications

Thomas RM†, Gamper CJ†, Ladle BH, Powell JD, Wells AD. De novo DNA methylation is required to restrict T helper lineage plasticity. Journal of Biological Chemistry. 2012; 287(27):22900-9. PMC3391093 †These authors contributed equally to these studies.

Thomas RM†, Gamper CJ†, Ladle BH, Powell JD, Wells AD. De novo DNA methylation is required to restrict T helper lineage plasticity. Journal of Biological Chemistry. 2012; 287(27):22900-9. PMC3391093 †These authors contributed equally to these studies.

Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, Huo J, Dezern AE, Steppan D, Robey N, Jo Holuba M, Cooke KR, Symons HJ. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. Biology of Blood and Marrow Transplant. 2016 May;22(5):895-901. PMCID pending.

Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ, Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies. Biology of Blood and Marrow Transplant. 2016 Jan;22(1):112-8. PMC4706497

Bolaños-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with post-transplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285-91. PMC3507140

Academic Affiliations & Courses

Courses and Syllabi

  • Classroom Instruction 10/06 – present Small group leader, Immunology, The Johns Hopkins University School of Medicine
  • Clinical Instruction 7/07 – 6/08 Morbidity & Mortality Coordinator, Pediatric Oncology, The Johns Hopkins University School of Medicine; Helped choose cases and supervise fellows presentations at Pediatric and Medical Oncology monthly M&M presentations
  • 3/11 – present Small group leader, Genes to Society, Leukemia, The Johns Hopkins University School of Medicine
  • CME Instruction 8/09 – 6/14 Organizer, Pediatric Oncology Case Conference, The Johns Hopkins University School of Medicine; Weekly multi-disciplinary conference held with Radiations Oncology, Pediatric Surgery, Radiology, and Pathology to review diagnostic studies and treatment planning for all active patients in the division; Didactic presentations by the fellows on service

Activities & Honors

Honors

  • Hyundai Scholar, 2008
  • 2008 – 2009 Hyundai Scholar, $40,000 award for support of Pediatric Oncology research, Hyundai Motor Corporation
  • 2009 – 2011 Cash Scholar, $36,000 per year, award for support of Pediatric Oncology research, Jonas Cash Foundation
  • 2010 – 2011 Hyundai Scholar, $60,000 award for support of Pediatric Oncology research, Hyundai Motor Corporation
  • 2012 SKCCC Director’s Teaching Award in Clinical Science
  • 2013 – 2014 Hyundai Scholar, $75,000 award for support of Pediatric Oncology research, Hyundai Motor Corporation

Memberships

  • ASCO, 2007
  • COG, 2008
  • American Society of Blood and Marrow Transplantation, 2010
Is this you? Edit Profile